Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines

Graziana Digiacomo(University of Florence), Pier Giorgio Petronini(University of Parma)
Frontiers in Oncology
September 23, 2020
10.3389/fonc.2020.563249
Cited by 31

Related Papers

Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway
|Cell Adhesion & Migration|2016|68
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
|Frontiers in Oncology|2019|48
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
|Molecular Cancer|2011|46